Literature DB >> 17706541

Drug metabolism in the paediatric population and in the elderly.

Margherita Strolin Benedetti1, Rhys Whomsley, Michael Canning.   

Abstract

This review focuses on one of the key factors accounting for differences in drug/metabolite exposure in paediatric and elderly subjects compared with that of the adult population, that is, differences in drug metabolism (both qualitative and quantitative) and in particular differences due to changes in the activity and/or concentration of drug metabolizing enzymes. Important differences have been found in the paediatric population compared with adults for both phase I (e.g. CYP3A7 versus CYP3A4 and CYP1A2, reductive and hydrolytic enzymes) and phase II (e.g. glucuronosyltransferases) enzymes. In the elderly, some phase I enzymes (e.g. esterases) appear to be impaired. From the information collected thus far, it would appear that phase II reactions, though sometimes decreased, are not extensively affected by old age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706541     DOI: 10.1016/j.drudis.2007.06.011

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  16 in total

1.  Therapeutic paracetamol treatment in older persons induces dietary and metabolic modifications related to sulfur amino acids.

Authors:  Estelle Pujos-Guillot; Gisèle Pickering; Bernard Lyan; Gilles Ducheix; Marion Brandolini-Bunlon; Françoise Glomot; Dominique Dardevet; Claude Dubray; Isabelle Papet
Journal:  Age (Dordr)       Date:  2011-02-22

Review 2.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

3.  BCRP protein levels do not differ regionally in adult human livers, but decline in the elderly.

Authors:  Zoe Riches; Ngu Abanda; Abby C Collier
Journal:  Chem Biol Interact       Date:  2015-10-14       Impact factor: 5.192

4.  A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.

Authors:  Robert M Ward; Gregory L Kearns; Brinda Tammara; Phyllis Bishop; Molly A O'Gorman; Laura P James; Mitchell H Katz; Mary K Maguire; Natalie Rath; Xu Meng; Gail M Comer
Journal:  J Clin Pharmacol       Date:  2010-09-17       Impact factor: 3.126

5.  Tissue distribution and proinflammatory cytokine gene expression following acute oral exposure to deoxynivalenol: comparison of weanling and adult mice.

Authors:  James J Pestka; Chidozie J Amuzie
Journal:  Food Chem Toxicol       Date:  2008-07-09       Impact factor: 6.023

6.  A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.

Authors:  Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane
Journal:  J Toxicol Environ Health A       Date:  2017-09-11

Review 7.  Pharmacokinetic drug interactions in liver disease: An update.

Authors:  Pietro Palatini; Sara De Martin
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

8.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.

Authors:  Natasa Djordjevic; Dragana Dragas Milovanovic; Marija Radovanovic; Ivan Radosavljevic; Slobodan Obradovic; Mihajlo Jakovljevic; Dragan Milovanovic; Jasmina R Milovanovic; Slobodan Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

Review 9.  Long-term consequences of drugs on the paediatric cardiovascular system.

Authors:  Elizabeth Hausner; Monica L Fiszman; Joseph Hanig; Patricia Harlow; Gwen Zornberg; Solomon Sobel
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 10.  Trichloroethylene: Mechanistic, epidemiologic and other supporting evidence of carcinogenic hazard.

Authors:  Ivan Rusyn; Weihsueh A Chiu; Lawrence H Lash; Hans Kromhout; Johnni Hansen; Kathryn Z Guyton
Journal:  Pharmacol Ther       Date:  2013-08-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.